Analyst Ratings For Ligand Pharmaceuticals (NASDAQ:LGND)
Today, HC Wainwright raised its price target on Ligand Pharmaceuticals (NASDAQ:LGND) to per share.
Some recent analyst ratings include
- 3/7/2018-Craig Hallum Reiterated Rating of Buy.
- 11/20/2017-Deutsche Bank was Downgraded by analysts at Deutsche Bank from a “Hold ” rating to a ” Sell” rating. They now have a $105.00 price target on the stock.
- 8/9/2017-Stephens Reiterated Rating of Overweight.
- 3/11/2016-Sidoti initiated coverage with a Buy rating.
- On 3/5/2018 John L Lamattina, Director, sold 3,335 with an average share price of $160.90 per share and the total transaction amounting to $536,601.50.
- On 2/27/2018 Todd C Davis, Director, sold 17,170 with an average share price of $152.37 per share and the total transaction amounting to $2,616,192.90.
- On 2/23/2018 Jason Aryeh, Director, sold 3,417 with an average share price of $155.00 per share and the total transaction amounting to $529,635.00.
- On 2/23/2018 Matthew W Foehr, COO, sold 5,444 with an average share price of $152.98 per share and the total transaction amounting to $832,823.12.
- On 2/15/2018 John L Higgins, CEO, sold 9,000 with an average share price of $157.03 per share and the total transaction amounting to $1,413,270.00.
- On 1/24/2018 John L Higgins, CEO, sold 22,500 with an average share price of $165.00 per share and the total transaction amounting to $3,712,500.00.
- On 1/19/2018 John L Higgins, CEO, sold 28,099 with an average share price of $153.70 per share and the total transaction amounting to $4,318,816.30.
Recent Trading Activity for Ligand Pharmaceuticals (NASDAQ:LGND)
Shares of Ligand Pharmaceuticals closed the previous trading session at 166.48 up +0.62 0.37% with 162.9752960205078 shares trading hands.